Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN M SLOMOVITZ

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1306885512
CMS profile
285884
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$93,445.64

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN M SLOMOVITZ

NPI 1306885512 · CMS profile ID 285884

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306885512?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN M SLOMOVITZ, NPI 1306885512, CMS profile ID 285884. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306885512?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRIAN M SLOMOVITZ, NPI 1306885512, CMS profile ID 285884. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306885512?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRIAN M SLOMOVITZ, NPI 1306885512, CMS profile ID 285884, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 142 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306885512?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $93,445.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $70.0010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141323185 CMS
Daiichi Sankyo Inc. $26.1510/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484249 CMS
Janssen Biotech, Inc. $14.0010/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078417257 CMS
Novartis Pharmaceuticals Corporation $14.5710/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158775 CMS
SOBI, INC $21.7110/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141413010 CMS
Eisai Inc. $18.8810/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734753 CMS
EMD Serono, Inc. $20.4110/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120272582 CMS
AstraZeneca Pharmaceuticals LP $24.8709/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105791594 CMS
Pharmacosmos Therapeutics Inc. $15.6509/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154826229 CMS
American Regent $24.9309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110517687 CMS
Daiichi Sankyo Inc. $2,055.0009/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484251 CMS
Daiichi Sankyo Inc. $1,712.5009/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484253 CMS
Genentech USA, Inc. $20.0809/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132982839 CMS
AstraZeneca Pharmaceuticals LP $525.0009/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105539653 CMS
Merck Sharp & Dohme LLC $1,000.0009/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141703597 CMS
Genmab U.S., Inc. $15.8009/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126825025 CMS
PFIZER INC. $134.9009/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131368993 CMS
Aveo Pharmaceuticals, Inc. $26.6009/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143474707 CMS
Eisai Inc. $815.0009/10/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734755 CMS
Merck Sharp & Dohme LLC $17.7609/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141637558 CMS
Myriad Genetic Laboratories, Inc. $40.8208/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152540367 CMS
Stemline Therapeutics Inc. $15.6308/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142958754 CMS
Astellas Pharma US Inc $32.7908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139400605 CMS
Daiichi Sankyo Inc. $29.0808/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484271 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.5708/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967924 CMS
Myriad Genetic Laboratories, Inc. $16.4507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152540365 CMS
Aadi Bioscience, Inc. $2,125.0007/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119596389 CMS
Aadi Bioscience, Inc. $112.5007/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119596391 CMS
Merck Sharp & Dohme LLC $915.0007/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141570414 CMS
AstraZeneca Pharmaceuticals LP $16.2107/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104682505 CMS
Lilly USA, LLC $18.0007/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136077713 CMS
Janssen Biotech, Inc. $22.1807/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078416993 CMS
Daiichi Sankyo Inc. $19.6307/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484269 CMS
Janssen Biotech, Inc. $26.3507/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078417212 CMS
Genentech USA, Inc. $22.2807/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132982835 CMS
AstraZeneca Pharmaceuticals LP $1,370.0007/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105711166 CMS
PFIZER INC. $1,575.0007/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131369706 CMS
Pharmacosmos Therapeutics Inc. $18.2706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154826227 CMS
Daiichi Sankyo Inc. $29.0106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089484267 CMS
Merck Sharp & Dohme LLC $2,117.5006/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141703599 CMS
Janssen Biotech, Inc. $28.3306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078417438 CMS
Deciphera Pharmaceuticals Inc. $23.0106/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145875433 CMS
Janssen Biotech, Inc. $21.3206/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078416592 CMS
Novartis Pharmaceuticals Corporation $14.8706/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158773 CMS
Merck Sharp & Dohme LLC $17.6506/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141955969 CMS
PFIZER INC. $195.9906/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131587139 CMS
Janssen Biotech, Inc. $21.8605/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078416554 CMS
Incyte Corporation $4,255.0005/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141293528 CMS
Karyopharm Therapeutics Inc. $62.0005/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145528326 CMS
Karyopharm Therapeutics Inc. $3,622.5005/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145528328 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,885.23 63
PY2020 $39,122.38 30
PY2021 $57,034.49 48
PY2022 $67,905.80 115
PY2023 $94,421.03 123
PY2024 $93,445.64 142
PY2025 $128,111.16 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,717,306.39 176
PY2024 Recipient $780.00 1
PY2024 Principal investigator $3,234,009.28 113
PY2023 Principal investigator $3,402,415.13 36
PY2022 Principal investigator $836,086.44 99
PY2021 Principal investigator $700,767.92 76
PY2020 Principal investigator $625,108.44 19
PY2019 Principal investigator $893,591.23 105

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

176 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $840.00 12/31/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202416688
Principal investigator 1 Aadi Bioscience, Inc. $1,254,942.74 12/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1255063048
Principal investigator 1 Merck Sharp & Dohme LLC $18,405.46 12/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemoth No dispute reported 06/30/2026 1232923676
Principal investigator 1 Merck Sharp & Dohme LLC $2,594.92 12/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors No dispute reported 06/30/2026 1232930575
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113077
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113079
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113081
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113083
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113085
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113087
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113171
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113173
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113175
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113177
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113179
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113063
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113065
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113067
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113069
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113071
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113073
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113075
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113155
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113157
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113159
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113161
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113163
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113165
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113167
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 12/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113169
Principal investigator 1 Aadi Bioscience, Inc. $495.00 12/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220112993
Principal investigator 1 Aadi Bioscience, Inc. $3,100.00 12/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113099
Principal investigator 1 Incyte Corporation $2,189.20 12/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477617
Principal investigator 1 ABBVIE INC. $6,420.33 12/04/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416791
Principal investigator 1 ABBVIE INC. $3,415.00 11/21/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416787
Principal investigator 1 Verastem, Inc. $427.95 11/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
RAMP 301 - GOG-3097 No dispute reported 06/30/2026 1207992673
Principal investigator 1 Verastem, Inc. $2,608.20 11/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
RAMP 301 - GOG-3097 No dispute reported 06/30/2026 1207992675
Principal investigator 1 Daiichi Sankyo Inc. $29,375.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-772 No dispute reported 06/30/2026 1223349082
Principal investigator 1 Daiichi Sankyo Inc. $29,375.00 11/17/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-854 No dispute reported 06/30/2026 1223349084
Principal investigator 1 Incyte Corporation $18,108.20 11/17/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477606
Principal investigator 1 Incyte Corporation $18,108.20 11/17/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477611
Principal investigator 1 PFIZER INC. $800.00 11/17/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709522
Principal investigator 1 PFIZER INC. $550.00 11/17/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709524
Principal investigator 1 Verastem, Inc. $3,441.00 11/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
RAMP 301 - GOG-3097 No dispute reported 06/30/2026 1207992671
Principal investigator 1 Aadi Bioscience, Inc. $1,200.00 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113005
Principal investigator 1 Aadi Bioscience, Inc. $1,200.00 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113007
Principal investigator 1 Aadi Bioscience, Inc. $1,600.00 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113095
Principal investigator 1 Aadi Bioscience, Inc. $1,600.00 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113097
Principal investigator 1 Verastem, Inc. $2,610.00 11/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
RAMP 301 - GOG-3097 No dispute reported 06/30/2026 1207992693
Principal investigator 1 Genmab U.S., Inc. $29,375.00 10/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235925993
Principal investigator 1 Genentech, Inc. $4,017.00 10/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
PD 1 LAG 3 in 1L Chemo ineligible mUC No dispute reported 06/30/2026 1211550747
Principal investigator 1 PFIZER INC. $550.00 10/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228711010
Principal investigator 1 Novartis Pharmaceuticals Corporation $461,050.74 10/08/2025 Non-covered Recipient Entity
SYLVESTER COMPREHENSIVE CANCER CENTER
A Phase II Trial of Letrozole plus Ribociclib in Women with Recurrent Low Grade Serous Carcinoma of the Ovary or Peritoneum No dispute reported 06/30/2026 1190309274
Principal investigator 1 Aadi Bioscience, Inc. $1,200.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113001
Principal investigator 1 Aadi Bioscience, Inc. $1,200.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113003
Principal investigator 1 Aadi Bioscience, Inc. $1,600.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113091
Principal investigator 1 Aadi Bioscience, Inc. $1,600.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113093
Principal investigator 1 Daiichi Sankyo Inc. $3,100.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349090
Principal investigator 1 PFIZER INC. $630.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709520
Principal investigator 1 PFIZER INC. $3,990.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709686
Principal investigator 1 PFIZER INC. $550.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709688
Principal investigator 1 PFIZER INC. $200.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709690
Principal investigator 1 PFIZER INC. $550.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709846
Principal investigator 1 PFIZER INC. $33,375.00 09/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228709848
Principal investigator 1 Incyte Corporation $310.80 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477568
Principal investigator 1 Incyte Corporation $1,563.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477571
Principal investigator 1 Incyte Corporation $21,729.84 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477576
Principal investigator 1 Incyte Corporation $5,473.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477580
Principal investigator 1 Incyte Corporation $23,163.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477583
Principal investigator 1 Incyte Corporation $2,500.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477587
Principal investigator 1 Incyte Corporation $5,473.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477591
Principal investigator 1 Incyte Corporation $5,473.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477596
Principal investigator 1 Incyte Corporation $5,473.00 09/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477601
Principal investigator 1 ABBVIE INC. $2,925.00 09/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416769
Principal investigator 1 ABBVIE INC. $4,515.00 09/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416773
Principal investigator 1 ABBVIE INC. $2,140.00 09/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416776
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246660662
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246660664
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246660666
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246660668
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246660670
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 08/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113059
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 08/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113061
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 08/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113153
Principal investigator 1 ABBVIE INC. $30,150.00 08/14/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer No dispute reported 06/30/2026 1202416758
Principal investigator 1 Daiichi Sankyo Inc. $360.00 08/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349094
Principal investigator 1 Aadi Bioscience, Inc. $1,200.00 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220112999
Principal investigator 1 Aadi Bioscience, Inc. $1,600.00 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113089
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113047
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113049
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113051
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113053
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113055
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113057
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113139
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113141
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113143
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113145
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113147
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113149
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 07/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113151
Principal investigator 1 ABBVIE INC. $13,365.69 07/22/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416751
Principal investigator 1 Genentech, Inc. $2,999.00 07/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
PD 1 LAG 3 in 1L Chemo ineligible mUC No dispute reported 06/30/2026 1211550743
Principal investigator 1 Daiichi Sankyo Inc. $2,165.00 07/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349092
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349096
Principal investigator 1 Daiichi Sankyo Inc. $43.94 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349098
Principal investigator 1 Daiichi Sankyo Inc. $17.70 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349100
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349102
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349104
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349106
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349108
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349110
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349112
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349114
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349116
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349118
Principal investigator 1 Daiichi Sankyo Inc. $17.70 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349120
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349122
Principal investigator 1 Daiichi Sankyo Inc. $13.15 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349124
Principal investigator 1 Incyte Corporation $6,200.00 06/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240477564
Principal investigator 1 ABBVIE INC. $546.60 05/27/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202416740
Principal investigator 1 Aadi Bioscience, Inc. $625.00 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220112995
Principal investigator 1 Aadi Bioscience, Inc. $625.00 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220112997
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113031
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113033
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113035
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113037
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113039
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113041
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113043
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113045
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113123
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113125
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113127
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113129
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113131
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113133
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113135
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 05/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113137
Principal investigator 1 Daiichi Sankyo Inc. $500.00 05/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349088
Principal investigator 1 ABBVIE INC. $1,500.00 05/15/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202416736
Principal investigator 1 ABBVIE INC. $625.00 05/12/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416729
Principal investigator 1 ABBVIE INC. $4,515.00 05/12/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416732
Principal investigator 1 ABBVIE INC. $610.00 05/09/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202416724
Principal investigator 1 Genentech, Inc. $4,767.00 04/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
PD 1 LAG 3 in 1L Chemo ineligible mUC No dispute reported 06/30/2026 1211550739
Principal investigator 1 ABBVIE INC. $2,430.00 04/14/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416714
Principal investigator 1 Genentech, Inc. $2,999.00 04/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
PD 1 LAG 3 in 1L Chemo ineligible mUC No dispute reported 06/30/2026 1211550735
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113023
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113025
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113027
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113029
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113117
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113119
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 03/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113121
Principal investigator 1 ABBVIE INC. $1,477.20 02/24/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202416685
Principal investigator 1 Aadi Bioscience, Inc. $360.00 02/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220112991
Principal investigator 1 ABBVIE INC. $900.00 02/06/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416699
Principal investigator 1 ABBVIE INC. $4,515.00 02/06/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202416702
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113009
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113011
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113013
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113015
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113017
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113019
Principal investigator 1 Aadi Bioscience, Inc. $1,411.83 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113021
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113101
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113103
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113105
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113107
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113109
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113111
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113113
Principal investigator 1 Aadi Bioscience, Inc. $3,261.06 01/30/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center of Florid
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer No dispute reported 06/30/2026 1220113115
Principal investigator 1 Genentech, Inc. $2,999.00 01/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
PD 1 LAG 3 in 1L Chemo ineligible mUC No dispute reported 06/30/2026 1211550730
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 01/08/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS600-109 No dispute reported 06/30/2026 1223349086
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,411,439.08 01/07/2025 Non-covered Recipient Entity
SYLVESTER COMPREHENSIVE CANCER CENTER
A Phase II Trial of Letrozole plus Ribociclib in Women with Recurrent Low Grade Serous Carcinoma of the Ovary or Peritoneum No dispute reported 06/30/2026 1190306175